- Project group leader, Assoc. professor PhD
- +47 2278 1719
› Project group leader in Computational Oncology & Assistant group leader in the Lothe lab.
› Associate Professor, Inst. Clinical Medicine, Faculty of Medicine, University of Oslo.
2012: PhD in cancer genomics, The Faculty of Medicine, University of Oslo, Norway.
2007: MSc in molecular biology, Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Areas of Research
› Genomics and transcriptomics for precision therapy of colorectal cancer
› Tumor heterogeneity modeling
› Molecular prediction models for risk assessment and treatment benefit
Prices and Scholarships
2018: Young Research Talent grant (Research Council of Norway)
2018: Postdoc grant (Regional Health Authority)
2017: Onkologisk Forum Young Investigator Award
2015: Personal researcher grant (Norwegian Cancer Society)
Most relevant publications
› Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, Dienstmann R, Nesbakken A, Lothe RA. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann Oncol 2018;29(5):1227-1234.
› Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA. Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies. Clin Cancer Res 2017;24(4):794-806.
› Eide PW, Bruun J, Lothe RA, Sveen A. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Sci Rep 2017;7(1):16618.
› Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA. Multilevel genomics of colorectal cancers with microsatellite instability - clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Med 2017;9(1):46.
› Sveen A, Løes IM, Alagaratnam S, Nilsen G, Høland M, Lingjærde OC, Sorbye H, Berg KC, Horn A, Angelsen JH, Knappskog S, Lønning PE, Lothe RA. Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genet 2016;12(7):e1006225.
› Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene 2015;35(19):2413-27.
› Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, Lothe RA. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012;61(11):1560-7.
Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains
Oncogene, 38 (33), 6109-6122
Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases
Eur J Surg Oncol (in press)
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
Ann Oncol (in press)
Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties
Int J Cancer, 144 (11), 2843-2853
Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage
Br J Cancer, 121 (6), 474-482
Combination therapies with HSP90 inhibitors against colorectal cancer
Biochim Biophys Acta Rev Cancer, 1871 (2), 240-247
Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
ESMO Open, 4 (3), e000523
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
Oncogenesis, 8 (6), 35
Biomarker-guided therapy for colorectal cancer: strength in complexity
Nat Rev Clin Oncol (in press)
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
Mol Oncol, 12 (9), 1639-1655
Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer
Int J Cancer, 144 (4), 841-847
Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53
Mod Pathol, 31 (11), 1694-1707
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
Ann Oncol, 29 (5), 1227-1234
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Mol Cancer, 16 (1), 116
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
Ann Oncol, 28 (5), 1023-1031
CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models
Sci Rep, 7 (1), 16618
Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Clin Cancer Res, 24 (4), 794-806
Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
Genome Med, 9 (1), 46
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Lancet Gastroenterol Hepatol, 1 (3), 207-216
Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness
Urol Oncol, 35 (3), 111.e1-111.e8
Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1
Cancer Lett, 385, 150-159
Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection
PLoS Genet, 12 (7), e1006225
Novel RNA variants in colorectal cancers
Oncotarget, 6 (34), 36587-602
TIN: An R Package for Transcriptome Instability Analysis
Cancer Inform, 14, 109-12
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
Oncogene, 35 (19), 2413-27
PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1
Biochem J, 461 (3), 383-90
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
Genes Chromosomes Cancer, 53 (7), 558-67
Transcriptome instability as a molecular pan-cancer characteristic of carcinomas
BMC Genomics, 15, 672
Transforming pluripotency: an exon-level study of malignancy-specific transcripts in human embryonal carcinoma and embryonic stem cells
Stem Cells Dev, 22 (7), 1136-46
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Clin Cancer Res, 19 (24), 6669-77
ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis
Gut, 61 (11), 1560-7
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements
Neoplasia, 14 (7), 600-11
The exon-level biomarker SLC39A14 has organ-confined cancer-specificity in colorectal cancer
Int J Cancer, 131 (6), 1479-85
ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients
Clin Cancer Res, 18 (21), 6001-10
Phospholipase C isozymes are deregulated in colorectal cancer--insights gained from gene set enrichment analysis of the transcriptome
PLoS One, 6 (9), e24419
Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival
Genome Med, 3 (5), 32
Genome-wide analysis of signal peptide functionality in Lactobacillus plantarum WCFS1
BMC Genomics, 10, 425
Heterologous protein secretion by Lactobacillus plantarum using homologous signal peptides
J Appl Microbiol, 105 (1), 215-26